A strategy map for the WA Comprehensive Cancer Centre was developed at a forum in August 2021.
A proposal was then distributed to potential key stakeholders including passionate and committed people with lived experience, doctors and other health professionals, researchers, leaders in cancer care, and representatives of other stakeholder groups.
On 27 March 2022, then-Prime Minister Scott Morrison announced $375 million funding for a comprehensive cancer centre for Western Australia to be developed. On 20 October 2022, Prime Minister Anthony Albanese confirmed the funding would be in the coming Federal Budget.
Subsequently, the West Australian government allocated $2.5 million to the Perkins for the purposes of developing a business case for the WA Comprehensive Cancer Centre. This process is currently underway.
On 2 May 2026, the Premier of Western Australia, The Hon Roger Cook MLA, announced the WA Govenrment would commit $375.6m to the Perkins WA Comprehensive Cancer Centre to be built on the QEII Medical Campus site. The Perkins will continue to work with the State Government to finalise the exact location at the QEII site through the QEII Master Plan process.
This bold addition to Western Australia’s health infrastructure will see WA join a national network of Comprehensive Cancer Centres, where the latest discoveries in bench side research can be more effectively trialled locally and translated into bedside treatment, setting Australia apart in developing new personalised treatment options for cancer patients.
The WA CCC Business Case Project Team consists of representatives from:
- WA Department of Health, including the Director General’s office
- Federal Government representatives from departments of Health and Finance
- State Government representatives from departments of Health and Finance
- Metropolitan Health Service providers (NMHS, SMHS and EMHS)
- Royal Perth, Fiona Stanley and Sir Charles Gairdner Hospitals
- West Australian Country Health Services (WACHS)
- Australian Medical Association
- The Harry Perkins Institute of Medical Research.
Perkins representatives on this project include:
- Chair The Hon Ben Morton
- Chief Executive Officer Prof Peter Leedman AO
- Deputy Director Prof Moira Clay
- Medical Oncologist Dr Peter Lau
- Cancer researcher Prof Andrew Redfern
- Haematologist Prof Chan Cheah
SEC Newgate is providing strategic consultation to the Perkins during this project. Hames Sharley have provided architectural consultation and sketches.